306 related articles for article (PubMed ID: 30377339)
1. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
Mésange P; Poindessous V; Sabbah M; Escargueil AE; de Gramont A; Larsen AK
Oncotarget; 2014 Jul; 5(13):4709-21. PubMed ID: 25015210
[TBL] [Abstract][Full Text] [Related]
4. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
5. Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A.
Burgermeister E; Battaglin F; Eladly F; Wu W; Herweck F; Schulte N; Betge J; Härtel N; Kather JN; Weis CA; Gaiser T; Marx A; Weiss C; Hofheinz R; Miller IS; Loupakis F; Lenz HJ; Byrne AT; Ebert MP
EBioMedicine; 2019 Jul; 45():139-154. PubMed ID: 31300350
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
[TBL] [Abstract][Full Text] [Related]
7. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.
Pineda E; Salud A; Vila-Navarro E; Safont MJ; Llorente B; Aparicio J; Vera R; Escudero P; Casado E; Bosch C; Bohn U; Pérez-Carrión R; Carmona A; Ayuso JR; Ripollés T; Bouzas R; Gironella M; García-Albéniz X; Feliu J; Maurel J
Tumour Biol; 2017 Jun; 39(6):1010428317705509. PubMed ID: 28621236
[TBL] [Abstract][Full Text] [Related]
8. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
9. FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA.
Wang S; Xiao Z; Hong Z; Jiao H; Zhu S; Zhao Y; Bi J; Qiu J; Zhang D; Yan J; Zhang L; Huang C; Li T; Liang L; Liao W; Ye Y; Ding Y
Cancer Lett; 2018 Dec; 439():78-90. PubMed ID: 30253191
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival.
Paiva TF; de Jesus VH; Marques RA; da Costa AA; de Macedo MP; Peresi PM; Damascena A; Rossi BM; Begnami MD; de Lima VC
BMC Cancer; 2015 Sep; 15():643. PubMed ID: 26394830
[TBL] [Abstract][Full Text] [Related]
12. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
13. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
14. Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.
Carbone C; Piro G; Simionato F; Ligorio F; Cremolini C; Loupakis F; Alì G; Rossini D; Merz V; Santoro R; Zecchetto C; Zanotto M; Di Nicolantonio F; Bardelli A; Fontanini G; Tortora G; Melisi D
Clin Cancer Res; 2017 Aug; 23(15):4312-4322. PubMed ID: 28298545
[No Abstract] [Full Text] [Related]
15. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours.
Coutelle O; Schiffmann LM; Liwschitz M; Brunold M; Goede V; Hallek M; Kashkar H; Hacker UT
Br J Cancer; 2015 Feb; 112(3):495-503. PubMed ID: 25562438
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of VEGF induces cellular senescence in colorectal cancer cells.
Hasan MR; Ho SH; Owen DA; Tai IT
Int J Cancer; 2011 Nov; 129(9):2115-23. PubMed ID: 21618508
[TBL] [Abstract][Full Text] [Related]
18. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
[TBL] [Abstract][Full Text] [Related]
19. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
[TBL] [Abstract][Full Text] [Related]
20. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.
Bachelier R; Confavreux CB; Peyruchaud O; Croset M; Goehrig D; van der Pluijm G; Clézardin P
Int J Cancer; 2014 Sep; 135(6):1319-29. PubMed ID: 24615579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
